All 13 patients with a median follow-upof 8.967 months (range 6.422~11.511) enrolled achieved CR for an overall response rate of 100%...The results of olverembatinib combined with PDT-ALL-2016 pediatric-inspired protocol continue to demonstrate excellent outcome results and acceptable safety data, indicating that this strategy maybe another standard of care approach in frontline Ph-positive ALL...